Retatrutide and Tirzepatide are both incretin-based therapies, with studies suggesting their primary utility in metabolic disease management, particularly for weight loss and improving cardiometabolic health. Retatrutide, a triple agonist, has shown significant weight loss and improvements in glycemic and lipid parameters in meta-analyses, indicating a broad therapeutic potential for obesity and related metabolic disorders. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has also demonstrated substantial weight loss in non-diabetic adults and broad health benefits extending to cardiovascular, renal, and liver protection, as supported by meta-analyses.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Drug class | glp 1 agonist, gip agonist, glucagon agonist | glp 1 agonist, gip agonist |
| Studies in corpus | 134 | 512 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | review · 49 preclinical animal · 11 meta analysis · 25 other · 21 rct · 23 in vitro · 1 | other · 50 cohort · 10 rct · 62 review · 24 case report · 9 preclinical animal · 7 case series · 1 meta analysis · 10 |
| Studies with explicit sample size | 2 | 29 |
| Head-to-head studies in corpus | 3 | |
Studies in our corpus that mention both Retatrutide and Tirzepatide — the gold-standard direct comparison evidence.
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated by newer agents like tirzepatide and sem…
This review underscores the transformative potential of novel antiobesity medications in improving cardiovascular health outcomes for obese patients. The demonstrated 20% reduction in MACE by semaglutide sets a new benchmark for pharmacotherapy in this high…
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of dual and triple incretin agonists offer…
No direct head-to-head trials in our corpus. Indirect comparison only. Retatrutide is characterized as a triple incretin agonist, while Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both peptides are noted for their efficacy in metabolic disorders, with reviews highlighting their potential to improve outcomes for individuals managing Type 2 Diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease (MASLD). While both show promise in cardiovascular benefits, specific studies on Retatrutide emphasize its impact on kidney transplant patients, showing improvements in metabolic parameters and a reduction in new-onset post-transplant diabetes mellitus. Tirzepatide's broader health benefits are suggested to extend to multi-organ protection, including cardiovascular disease, chronic kidney disease, and non-alcoholic fatty liver disease, potentially independent of its metabolic effects. The corpus includes a higher number of studies on Tirzepatide (536) compared to Retatrutide (140), potentially indicating a more extensive body of research for Tirzepatide at this time.
Looking for vendor-level purity, endotoxin, and HPLC data on Retatrutide or Tirzepatide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.